TDOC · Teladoc Health, Inc.

Current Thesis

Teladoc Health’s remaining case is cash-flow support while BetterHelp stabilises; the next quarterly results must confirm that case before a weekly close below $6.00 breaks the published support level. The measurable resolution is Q3 2026 revenue meeting the $569 million guidance floor, BetterHelp average paying users holding at least Q2’s 0.346 million, and the FY2026 free-cash-flow guidance floor remaining $130 million. Those benchmarks come from Teladoc’s 2026-07-29 results. Q2 results

The change since the 2026-09-06 assessment is BetterHelp’s 2026-09-09 national advertising campaign and disclosure of more than 125 health-plan relationships reaching more than 150 million contracted lives. That documents distribution reach; the release supplies no new segment revenue or average-paying-user result. It therefore does not establish that insurance reimbursement is offsetting subscription weakness. BetterHelp release, distributed by Business Wire

The inference remains that the pivot narrative is dead — the 2026-07-29 revenue-guidance reduction remains unreversed in the disclosures reviewed, and the 2026-09-18 adjusted close of $6.30 remains below the $6.50 reference close recorded on 2026-08-28. Confirmation of the quarterly benchmarks above would overturn that interpretation.

Bullish and bearish views on Teladoc Health, Inc.

The model's bull view on Teladoc Health, Inc. (TDOC), in brief: Cash-flow guidance remains the anchor. Teladoc’s 2026-07-29 release retained FY2026 free-cash-flow guidance of $130–170 million despite reducing revenue guidance. Neither figure alone establishes an equity valuation floor. Integrated Care retains positive growth. Q2 2026 segment… The bear view: BetterHelp still shows contraction. The 2026-07-29 results reported Q2 2026 BetterHelp revenue of $212.6 million, down 12% year over year, and average paying users of 0.346 million versus 0.361 million in Q1 2026. These observations establish deterioration across the reported… Both cases follow in full.

Bull Case

• Cash-flow guidance remains the anchor. Teladoc’s 2026-07-29 release retained FY2026 free-cash-flow guidance of $130–170 million despite reducing revenue guidance. Neither figure alone establishes an equity valuation floor.
• Integrated Care retains positive growth. Q2 2026 segment revenue was $394.3 million, up 1% year over year, according to the 2026-07-29 release. This supports the stabilisation case only while the larger segment continues growing.
• Insurance distribution has documented reach. BetterHelp’s 2026-09-09 release reported more than 125 health-plan relationships. Whether that access produces paying users remains unresolved until subsequent operating disclosures. Company release

Bear Case

• BetterHelp still shows contraction. The 2026-07-29 results reported Q2 2026 BetterHelp revenue of $212.6 million, down 12% year over year, and average paying users of 0.346 million versus 0.361 million in Q1 2026. These observations establish deterioration across the reported periods, without establishing when it ends.
• Consolidated guidance already required revision. On 2026-07-29, Teladoc reduced FY2026 revenue guidance to $2,362–2,447 million. A further reduction below that range’s lower bound would contradict the stabilisation case. Q2 results and outlook
• Marketing disclosure leaves economics unresolved. The 2026-09-09 BetterHelp announcement provides no updated revenue, customer-acquisition cost or average-paying-user figure. Advertising activity cannot establish improving commercial returns without those measurements. Company release

Setup & Price Structure

The supplied adjusted daily series places the 2026-09-18 close at $6.30, down 16.9% over three months and 35.2% below its $9.72 52-week high. The $6.00 support threshold retained from the 2026-09-06 assessment remains the research invalidation level. The latest close remains above it, but the supplied observations do not establish a completed base.

Positioning evidence is insufficient. The supplied 2026-07-08 Benzinga headline records renewed attention to the Walmart partnership; a single article cannot establish clustered retail participation. No current short-interest measure, insider-sale series or moving-average level is available in the dated evidence, so neither crowding nor distance above a rising average can be established.

Catalyst Calendar (next 30 days)

• 2026-09-20 through 2026-10-20: No confirmed company event appears on Teladoc’s investor calendar as checked on 2026-09-20. This is a calendar observation, not a forecast that no announcement will occur. Company event calendar
• ~2026-10-28, estimated and unconfirmed: The previously published working date for Q3 2026 results remains outside this window. The company calendar does not confirm it; the prior-year results occurred on 2025-10-29. The report would test the revenue, paying-user and cash-flow benchmarks stated above. Q3 2025 results

What Would Change Our Mind

Loss of the published support threshold would end the cash-flow-supported stabilisation case: a weekly close below $6.00 is the price condition. Independently, Q3 2026 revenue below the $569 million guidance floor or FY2026 free-cash-flow guidance below $130 million would break its operating premise. Both financial thresholds were published on 2026-07-29.

The opposing evidence would be Q3 2026 revenue meeting that floor, BetterHelp average paying users at least matching Q2 2026’s 0.346 million, and unchanged or higher full-year cash-flow guidance before the price condition occurs. That would satisfy this narrow thesis; it would not by itself establish renewed growth.

Correlation Notes

This remains a single-name setup. Teladoc’s 2026-07-29 segment disclosure showed Integrated Care growing while BetterHelp contracted, giving the consolidated business distinct demand exposures. No paired return series is supplied as of 2026-09-18, so a measured correlation with managed-care equities or other telehealth companies cannot be stated. The thesis therefore receives no assumed support from a sector rally.